These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 90689)

  • 1. Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?
    Schleusener H; Finke R; Kotulla P; Wenzel KW; Meinhold H; Roedler HD
    J Endocrinol Invest; 1978 Apr; 1(2):155-61. PubMed ID: 90689
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating immune complexes and thyroid-stimulating immunoglobulins before, during, and after antithyroid drug therapy in patients with Graves' disease.
    van der Heide D; Daha MR; Bolk JH; Bussemaker JK; de Bruin TW; Goslings BM; van Es LA; Querido A
    Lancet; 1980 Jun; 1(8183):1376-9. PubMed ID: 6155582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of the assay of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease: Effect of antithyroid drug treatment on TBII and prognosis].
    Iida Y; Konishi J; Kousaka T; Misaki T; Nakajima T; Endo K; Torizuka K
    Kaku Igaku; 1983 Dec; 20(10):1425-31. PubMed ID: 6202910
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are pituitary and thyroid function tests useful for the monitoring of antithyroid drug treatment and the post therapeutic control of Graves' disease?
    Jaffiol C; Baldet L; Castelnau P; Papachristou C; Lapinski H; Rouaud R
    Horm Res; 1987; 26(1-4):137-45. PubMed ID: 2439427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid stimulating immunoglobulin in Graves' disease.
    Luttrell BM; Hales IB
    Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration of TSH-receptor antibodies (TBII) in the sera of patients with immunogenic hyperthyroidism (Graves' disease) receiving antithyroid medication.
    Budihna N; Pavlin K; Porenta M
    Radiobiol Radiother (Berl); 1987; 28(1):101-6. PubMed ID: 2438715
    [No Abstract]   [Full Text] [Related]  

  • 9. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
    Wenzel KW; Lente JR
    J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.
    Lamberg BA; Aro A; Saarinen P; Tötterman T; Mäkinen T
    J Endocrinol Invest; 1978 Jan; 1(1):9-16. PubMed ID: 90688
    [No Abstract]   [Full Text] [Related]  

  • 11. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization and clinical assessment of a radioreceptor assay for thyrotropin-binding inhibitor immunoglobulins.
    Konishi J; Kasagi K; Iida Y; Kousaka T; Misaki T; Arai K; Tokuda Y; Torizuka K
    Endocrinol Jpn; 1987 Feb; 34(1):13-20. PubMed ID: 2440665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins.
    Bech K
    Acta Endocrinol Suppl (Copenh); 1983; 254():3-38. PubMed ID: 6191508
    [No Abstract]   [Full Text] [Related]  

  • 14. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease.
    Bliddal H; Bech K; Kirkegaard C
    Horm Metab Res; 1984 Nov; 16(11):602-5. PubMed ID: 6210237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
    Kung AW; Lau KS; Kohn LD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological parameters in Graves' disease: are they useful for indication and monitoring of antithyroid drug treatment?
    Orgiazzi J; Madec AM; Genetet N; Gueguen M; Allannic H
    Horm Res; 1987; 26(1-4):131-6. PubMed ID: 2439426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
    Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.